Newer strategies for the treatment of heparin-induced thrombocytopenia.
Treatment with heparin is associated with two types of thrombocytopenia. One is a mild, transient, nonimmune disorder, generally without adverse clinical consequence. The other, known as heparin-induced thrombocytopenia (HIT), is a potentially serious, immunoglobulin-mediated reaction with a paradoxic high risk of thromboembolic events. Various treatment options for HIT are discussed, with emphasis on pharmacologic approaches that control the increased thrombin generation characteristic of this disorder.
Department of Laboratory Medicine, Hamilton Health Sciences Corporation, McMaster University, Ontario, Canada.
T E
TE
Warkentin
R L
RL
Barkin
D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy / Q000628:therapy*
D006493:Heparin